Validation of Simultaneous Quantitative Method of HIV Protease Inhibitors Atazanavir, Darunavir and Ritonavir in Human Plasma by UPLC-MS/MS

<table>Product ion mass spectra of (a) atazanavir (<i>m/z</i> 705.3 → 167.9, scan range 100–750 amu) (b) darunavir (<i>m/z</i> 548.1 → 392.0, scan range 200–650 amu), and (c) ritonavir (<i>m/z</i> 721.3 → 296.3, scan range 200–750 amu) in the positive ionization mode.</table>

The Scientific World Journal

fig2

Figure 2

Figure 2: Validation of Simultaneous Quantitative Method of HIV Protease Inhibitors Atazanavir, Darunavir and Ritonavir in Human Plasma by UPLC-MS/MS 

Figure 2 | Validation of Simultaneous Quantitative Method of HIV Protease Inhibitors Atazanavir, Darunavir and Ritonavir in Human Plasma by UPLC-MS/MS 